Halofuginone regulatory update

FDA granted Orphan Drug designation for Halo's HT-100 to treat Duchenne muscular dystrophy (DMD). Halo plans to begin a Phase II trial of the oral analog of halofuginone, a collagen type I (COL1) inh...